In the Spotlight - Although the mid-December hookup of Amgen Inc. and Immunex Corp. is not expected to touch off a round of reactionary dealmaking in the biotech industry, industry experts think that as companies look to expand their product portfolios and add infrastructure to manage product marketing and distribution, m&a will serve as an attractive avenue of growth for them.
|Year of Publication:||
|Type of Publication:||Article|
|Title record from database:|| OLC-SSG Economic Sciences|
|Availability:||More access options|
|More options (other):|
|Description not available.|